Form 4: Vera Therapeutics Director Acquires Stock Options

Andrew Cheng, a Director at Vera Therapeutics, Inc., acquired 17,084 stock options with an exercise price of $34.35, vesting in full on May 20, 2036, or earlier upon a change in control.

Summary

• Andrew Cheng, a Director of Vera Therapeutics, Inc., acquired 17,084 stock options on May 21, 2026.
• The options have an exercise price of $34.35 per share.
• These options are set to vest in full on May 20, 2036, or earlier if a change in control occurs, provided continuous service is maintained.
• The filing indicates that the reporting person is not subject to Section 16 reporting requirements and that this transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity award to a director as part of their compensation, rather than a significant event impacting the company's financial performance or strategic direction.

Positives

• Director Andrew Cheng has acquired a significant number of stock options, indicating a commitment to the company's future performance.
• The acquisition is part of a pre-arranged plan (Rule 10b5-1(c)), suggesting a structured approach to equity management.
• The vesting schedule includes acceleration upon a change in control, aligning the director's interests with potential shareholder value in such an event.

Negatives

• The filing does not disclose the grant date of the options, only the transaction date.
• The exercise price of $34.35 is significantly higher than the current market price (implied by the lack of immediate exercise and the nature of options granted to directors), suggesting potential future upside is needed for these options to be in-the-money.

Risks

• The value of the acquired options is contingent on the future stock price of Vera Therapeutics, Inc. exceeding the exercise price of $34.35.
• The vesting is subject to the reporting person's continuous service, meaning any departure before the vesting date would result in forfeiture of the unvested options.

Future Outlook

The future outlook for the acquired options is dependent on the company's stock performance and the director's continued service. The options are exercisable at $34.35 and vest on May 20, 2036, or earlier upon a change in control.

Management Comments

• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
• Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term company growth and shareholder value. The specific terms, including the exercise price and vesting schedule, are critical indicators of management's confidence in future stock appreciation.

Stakeholder Impact

• Shareholders: The grant of options to directors is a standard compensation practice. The value realized by the director is directly tied to future stock performance, aligning their interests with shareholders.
• Employees: This filing does not directly impact employees, but it reflects a compensation strategy that may be mirrored in employee equity programs.
• Management: Andrew Cheng's compensation is enhanced by this option grant, contingent on company performance and continued service.

Next Steps

• Andrew Cheng will continue to provide service to Vera Therapeutics, Inc. through the vesting dates.
• The company's stock performance will determine the ultimate value of the acquired options.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity Award, Rule 10b5-1